Carfilzomib in multiple myeloma
Frontiers | Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma | Oncology
Carfilzomib - JADPRO
Late Breaking Abstract – ASH 2019: DARZALEX®, KYPROLIS® and Dexamethasone Combination Improves PFS in Relapsed or Refractory Multiple Myeloma – OncoPrescribe
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study - The Lancet
Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin - ScienceDirect
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma | Leukemia
Carfilzomib: new drug for multiple myeloma - info-farmacia
Bortezomib-Resistant Mutant Proteasomes: Structural and Biochemical Evaluation with Carfilzomib and ONX 0914 - ScienceDirect
Cancers | Free Full-Text | Multiple Myeloma: Available Therapies and Causes of Drug Resistance | HTML
Mechanism of action of ixazomib. Notes: Ixazomib (MLN9708) administered... | Download Scientific Diagram
Resistance Mechanisms to Novel Therapies in Myeloma | IntechOpen
Novel Targeted Agents in the Treatment of Multiple Myeloma - Hematology/Oncology Clinics
Figure 1 from Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma. | Semantic Scholar
The Role of Proteasome Inhibitors in Treating Acute Lymphoblastic Leukaemia | Oncology - Frontiers
Updates to the drug‐resistant mechanism of proteasome inhibitors in multiple myeloma - Bai - 2021 - Asia-Pacific Journal of Clinical Oncology - Wiley Online Library
Proteasome inhibitors - ScienceDirect
IJMS | Free Full-Text | Cellular Responses to Proteasome Inhibition: Molecular Mechanisms and Beyond | HTML
New investigational drugs with single-agent activity in multiple myeloma | Blood Cancer Journal
Kyprolis FOCUS Phase 3 Study for Multiple Myeloma | Cancer Biology
Proteasome Inhibitors as Sensitizing Agents for Cancer Chemotherapy - ScienceDirect
Carfilzomib for relapsed and refractory multiple myeloma | CMAR
Carfilzomib - Wikipedia
H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth | Scientific Reports
Molecules | Free Full-Text | Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease | HTML
